Summary:
ASCO-GU is taking place from Feb 16-19 and abstracts will be released Feb 13
This conference will focus on genitourinary cancers such as prostate cancer and ovarian cancer
Several smid-cap biopharmas are presenting data at ASCO-GU, including final results from BTAI
We have also determined additional upcoming late stage trials in GU cancers in the next year
Make a free account to see our full analysis of these companies including more info on BTAI! As well as our previous article including other future GU cancer readouts
ASCO-GU 2023 starts February 16 and focuses on new and innovative findings and studies for the treatment of genitourinary malignancies. Abstracts will be released February 13 at 5pm ET and late breaking abstracts will be released on the day of presentation at 7am PT. Currently we know of 5 companies in our database of smid-cap biopharmas that are presenting data at ASCO-GU 2023. These companies focus on genitourinary cancers, such as prostate cancer and ovarian cancer. See these companies as well as a summary of data to be presented in Table 1. We expect to see additional companies announce involvement when abstracts are released.
Currently BTAI's presentation of full Phase 2 BXCL701 data is a BPIQ Suspected Mover (See all February Suspected/ Big Movers HERE after subscribing. Learn more here), below is more info on this trial.
Table 1. ASCO-GU 2023 smid-cap biopharma presentations
BTAI BXCL701 Data
Data from the Phase 2 trial of BTAI's asset BXCL701 + KEYTRUDA to treat rare prostate cancer was first reported January 11, 2023. The company stated the trial showed promising topline data that demonstrated an encouraging response rate in metastatic castration-resistant prostate cancer (mCRPC). The January report was very limited and without specific data, it was stated full data would be presented at ASCO-GU, making us label it as a Suspected Mover for the month.
See more info on the upcoming BTAI readout in our full analysis HERE. Sign up for free with your email!
Upcoming GU readouts
Other mCRPC assets with upcoming readouts include MGNX (Ph1), LVTX (Ph1/2), AZN (PDUFA), FMTX (Ph1), RCUS (Ph1/2), EXEL (Ph3), MGNX (Ph2) and more. There are many other readouts coming in the next year and beyond in the genitourinary cancer area, as can be seen in Table 2.
See our full analysis for assets past H1 2023 by signing up for FREE with your email!
Table 2. Upcoming H1 2023 GU cancer readouts
See what our members are saying about us:
Mike from United States
“Really loving the site over the competitor... like the layout and speed over the competition...like the individual pages for each drug/treatment”
Carl from United States
“I like your service. I haven’t seen anyone else doing something similar...nothing like this available for retail.”
Essey from Canada
“Love what you’re doing, this website is awesome.”
James from United States
Great site and I see it’s a family run business, great job.”